J&J Settlement With States Not Likely To Be Precedent In OTC Space
This article was originally published in The Pink Sheet
Executive Summary
J&J's agreement with 42 states and Washington, D.C. is its latest cost from widespread GMP problems that prompted recalls and led to a 2011 FDA consent decree. But the unusual combination of factors suggest more such state actions are unlikely to follow.
You may also be interested in...
J&J/McNeil Completes Remediation Under Consent Decree
FDA officials on Aug. 21 notified the firm that its Fort Washington, Pa., manufacturing plant is compliant with the agency’s GMP regulations for drugs.
Glaxo In Charge, And The World Is GSK/Novartis Consumer Product JV’s Oyster
GSK Consumer Healthcare not only is the name of Glaxo/Novartis JV, but also the brand being added to Novartis’ OTC products. The JV will access OTC switch opportunities across the Rx portfolios of both Glaxo and Novartis in addition to external partners, says Americas/Europe head Brian McNamara.
GNC Targets ‘Consumer Trust’ In N.Y. Agreement, But Industry Wary Of Impact
As GNC explains why it accepted an agreement with N.Y. to resolve accusations about adulterated herbal supplements, industry stakeholders at Ingredient Marketplace discuss strategies on refuting those allegations and informing consumers about the quality control that is a hallmark for much of the industry.